SCHEMBL4276586

SCHEMBL4276586

NCCCC(OP(=O)(O)OP(=O)(O)O)(P(=O)(O)O)P(=O)(O)O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FDPS P14324 9/20 0.47
PDE3A Q14432 2/20 0.47
LMNA P02545 2/20 0.36
ADRB3 P13945 1/20 0.36
PDE4D Q08499 1/20 0.36
BLM P54132 2/20 0.34
CYP3A4 P08684 1/20 0.34
NFKB1 P19838 1/20 0.34
PMP22 Q01453 1/20 0.34
SMPD1 P17405 3/20 0.33
GABBR2 O75899 1/20 0.32
CYP1A2 P05177 1/20 0.32
TSHR P16473 1/20 0.32
THPO P40225 1/20 0.32
GABBR1 Q9UBS5 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17499972 0.84 FDPS (0.54) FDPSPDE3ALMNAADRB3PDE4D
SCHEMBL5277592 0.76 FDPS (0.58) FDPSPDE3ALMNAADRB3PDE4D
SCHEMBL27661427 0.75 FDPS (0.37) FDPSPDE3ALMNABLMSMPD1
SCHEMBL177948 0.73 FDPS (0.66) FDPSPDE3ALMNAADRB3PDE4D
SCHEMBL21959040 0.72 FDPS (0.54) FDPSPDE3ALMNAADRB3PDE4D
Pyrophosphoric Acid SCHEMBL17311814 0.70 FDPS (0.59) FDPSPDE3ALMNABLMCYP3A4
Pyrophosphoric Acid SCHEMBL17311822 0.70 FDPS (0.59) FDPSPDE3ALMNABLMCYP3A4
SCHEMBL5459582 0.69 FDPS (0.35) FDPSPDE3ALMNAADRB3PDE4D
SCHEMBL5455779 0.68 BTN3A1 (0.42) FDPSBLMSMPD1TDP1
SCHEMBL8169756 0.68 ITPR3 (0.53) LMNABLMCYP3A4NFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150157649-A1 LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE INTERNATIONAL MEDICATION SYSTEMS, LIMITED 2015-06-11 US disclosed
US-20150157650-A1 LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE INTERNATIONAL MEDICATION SYSTEMS, LIMITED 2015-06-11 US disclosed
US-8974801-B2 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate AMPHASTAR PHARMACEUTICALS INC. (US) 2015-03-10 US disclosed
EP-2548441-B1 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate AMPHASTAR PHARMACEUTICALS INC (US) 2014-08-27 EP disclosed
CN-101616591-B Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate AMPHASTAR PHARMACEUTICALS INC 2014-06-18 CN disclosed
EP-2548441-A1 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate Amphastar Pharmaceuticals Incorporation (US) 2013-01-23 EP disclosed
EP-2120585-B1 LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE AMPHASTAR PHARMACEUTICALS INC (US) 2012-10-03 EP disclosed
CN-101616591-A The long term sustained release pharmaceutical composition that comprises the aqueous suspension of bisphosphonate AMPHASTAR PHARMACEUTICALS INC 2009-12-30 CN disclosed
EP-2120585-A1 LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE Amphastar Pharmaceuticals Incorporation (US) 2009-11-25 EP disclosed
WO-2008085281-A1 LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE AMPHASTAR PHARMACEUTICALS, INC. (US) 2008-07-17 WO disclosed
US-20080153784-A1 LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153784-A1 LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE SOST, PTH1R, BPGM FDPS 841/4885PDE3A 326/4885LMNA 4276/4885
US-20150157650-A1 LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE SOST, PTH1R, BPGM FDPS 841/4885PDE3A 326/4885LMNA 4276/4885
US-20150157649-A1 LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE SOST, PTH1R, BPGM FDPS 841/4885PDE3A 326/4885LMNA 4276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.